表面活性蛋白A和D减轻LPS诱导的原代肠上皮细胞凋亡
该研究利用SP-A/D基因敲除与野生型小鼠的原代肠上皮细胞,探讨SP-A和SP-D对LPS诱导凋亡的调控。结果显示,SP-A/D敲除细胞的LPS诱导凋亡、caspase-3、BAX/Bcl-2及p-P38/t-P38 MAPK升高更明显;给予SP-A或SP-D可减弱野生型细胞的上述LPS诱导升高。P38激动剂U46619增加凋亡,SP-A/D可减弱该效应;P38抑制剂SB203580减弱LPS诱导凋亡,再加SP-A或SP-D可完全改善凋亡。SP-A/D还阻止LPS诱导的TLR4和CD14表达升高。
要点
- SP-A/D敲除原代肠上皮细胞在LPS刺激24小时后,凋亡、cleaved caspase-3、BAX/Bcl-2及p-P38/t-P38 MAPK升高较野生型更明显。
- 野生型原代肠上皮细胞先给予SP-A或SP-D处理20小时、再LPS刺激24小时,可减弱LPS诱导的凋亡、cleaved caspase-3、BAX/Bcl-2及p-P38/t-P38 MAPK升高。
- P38激动剂U46619增加肠上皮细胞凋亡、caspase-3及BAX/Bcl-2,SP-A/D可减弱该效应;P38抑制剂SB203580减弱LPS诱导的凋亡、caspase-3及BAX/Bcl-2。
- SB203580基础上加入SP-A或SP-D可完全改善LPS诱导的凋亡;SP-A/D阻止LPS诱导的TLR4和CD14表达升高。
适用人群与场景
- 研究使用从SP-A/D基因敲除小鼠或C57BL/6野生型小鼠建立的原代肠上皮细胞,体外LPS刺激模型,非临床患者人群。
研究设计与关键结果
- 研究类型为体外细胞实验;原代肠上皮细胞来自SP-A/D敲除或C57BL/6野生型小鼠,LPS刺激后24小时收获;野生型细胞给予SP-A、SP-D或溶媒20小时后,再LPS刺激24小时。
- LPS诱导的凋亡、caspase-3水平、BAX/Bcl-2及p-P38/t-P38 MAPK在SP-A/D敲除肠上皮细胞中升高。
- SP-A和SP-D减弱野生型肠上皮细胞中LPS诱导的凋亡、cleaved caspase-3、BAX/Bcl-2及p-P38/t-P38 MAPK升高。
- U46619增加肠上皮细胞凋亡、caspase-3及BAX/Bcl-2,该效应被SP-A/D减弱;SB203580减弱野生型肠上皮细胞中LPS诱导的凋亡、caspase-3及BAX/Bcl-2升高。
- 在SB203580基础上加入SP-A或SP-D可完全改善LPS诱导的凋亡。
- LPS诱导的TLR4和CD14表达升高在SP-A/D敲除肠上皮细胞中更明显;用SP-A或SP-D处理野生型肠上皮细胞可阻止LPS诱导的TLR4和CD14升高。
证据类型、等级与局限
- 证据类型:体外细胞实验(原代肠上皮细胞)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为体外原代肠上皮细胞实验,未给出临床推荐;结果提示SP-A和SP-D可能通过抑制TLR4及P38 MAPK信号通路减轻LPS诱导的肠上皮细胞凋亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: SP-A/D KO mice with sepsis demonstrate more severe lung, kidney, and gut injury/apoptosis than WT controls. We hypothesize SP-A and SP-D directly regulate lipopolysaccharide (LPS)-induced P38 mitogen-activated protein kinase (MAPK) activation and gut apoptosis during sepsis.
METHODS: Primary IECs were established from SP-A/D KO or C57BL/6 WT mice, stimulated with LPS and harvested at 24 h. IECs from WT mice were treated with SP-A, SP-D, or vehicle for 20 h, then LPS for 24 h. Apoptosis, cleaved caspase-3 levels and the ratio of BAX/Bcl-2 were assayed. The role of P38 MAPK was examined using the P38 MAPK-agonist U46619 and inhibitor SB203580 in LPS-treated cells. p-P38 MAPK/t-P38 MAPK, TLR4, and CD14 were measured by Western Blot.
RESULTS: LPS-induced apoptosis, caspase-3 levels, BAX/Bcl-2, and p-P38/t-P38 MAPK were increased in SP-A/D KO IECs. SP-A and SP-D attenuate LPS-induced increase in apoptosis, cleaved caspase-3, BAX/Bcl-2, and p-P38/t-P38 MAPK in WT IECs. U46619 increased apoptosis, caspase-3, and BAX/Bcl-2 in IECs which was attenuated by SP-A/D. SB203580 attenuates the LPS-induced increase in apoptosis, caspase-3, and BAX/Bcl-2 in WT IECs. Addition of SP-A or SP-D to SB203580 completely ameliorates LPS-induced apoptosis. The LPS-induced increase in TLR4 and CD14 expression is greater in IECs from SP-A/D KO mice and treatment of WT IECs with SP-A or SP-D prevents the LPS-induced increase in TLR4 and CD14.
CONCLUSIONS: SP-A and SP-D attenuate LPS-induced increases in apoptosis, caspase-3, and BAX/Bcl-2 in IECs. Attenuation of LPS-induced activation of TLR4 and P38 MAPK signaling pathways represents potential mechanisms for the protective effects of SP-A/D on apoptosis.
参考来源
- Zhang L, Meng Q, Yepuri N, et al. Surfactant Proteins-A and -D Attenuate LPS-Induced Apoptosis in Primary Intestinal Epithelial Cells (IECs). Shock. 2018. PMID: 28591009. doi:10.1097/SHK.0000000000000919
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。